医学捌号楼
 
Web www.med8th.com
首页 | 医疗资讯 | 人与医学 | 阅览室 | 诺贝尔奖 | 专业资源 | 院士录 | 中医
医学捌号楼・皮肤科・

Rosetta Biosoftware公司和Ingenuity Systems公司将提供Rosetta Resolver系统与Ingenuity Pathways Analysis系统间的互用性能


管理员  | 2013-04-22 13:34:44

(BW)(WA-ROSETTA-BIOSOFTWARE)(MRK) Rosetta Biosoftware公司和Ingenuity Systems公司将提供Rosetta Resolver系统与Ingenuity Pathways Analysis系统间的互用性能

美国商业新闻2006年1月25日加利福尼亚州西雅图和红木城消息――

Rosetta Biosoftware公司和Ingenuity Systems公司今天宣布进行协作,建立Rosetta Resolver?系统与Ingenuity Pathways Analysis系统之间的互用性。研究人员将能够更加容易地在这两个系统之间交换数据,利用这两个系统的性能来分析基因表达数据及进行先进的路径分析。 

Rosetta Biosoftware公司总经理兼副总裁Yelena Shevelenko说:“Rosetta Resolver系统是一个针对分析潜伏期和临床研究大量数据或用于研究诊断的综合信息解决方案。我们非常高兴把Ingenuity公司的路径分析工具和Rosetta Resolver系统无缝整合,提供给我们共同的客户,支持它们揭示活动机理,预测潜在毒性,这对它们的基因表达数据具有生物学上的意义。”

Ingenuity Systems 公司合作伙伴兼专业服务事业部副总裁Tuan Nguyen说:“把Ingenuity Pathway Analysis解决方案与Resolver系统结合在一起,将能够增加我们共同客户的能力,从基因表达数据中获取更多的理解及洞察力。此次协作是我们把Ingenuity Pathways Analysis无缝整合到我们客户自然工作流过程中的一个重要步骤。”

Rosetta Resolver系统由Rosetta Biosoftware公司开发,由Agilent Technologies公司专门负责分销。

关于Ingenuity Systems公司

Ingenuity公司支持研究人员模拟、分析以及理解人类健康及疾病的复杂的生物系统基础。Ingenuity公司的产品包括针对生物学家和生物信息学家的路径分析软件和基础知识、企业知识管理基础设施、针对领先的制药及生物技术公司的内容和服务。Ingenuity公司成立于1998年,总部位于加利福尼亚州的红木城(Redwood City),公司在德国、瑞士、淄、英国及日本均设有办事处。欲了解详细情况,可访问网站 www.ingenuity.com 。

关于Rosetta Resolver系统

Rosetta Resolver系统是一种高性能的基因表达数据存储、恢复与分析解决方案。该系统是那些需要评估化合物特性或毒性,识别新基因或者治疗目标以及比较与分析大型基因表达特性数据库的生命科学研究机构的理想工具。Rosetta Resolver系统结合了灵活机动、操作简单以及高精确计算的性能,能够提供基因表达数据快速分析的全面解决方案。Rosetta Resolver系统能够接收与分析包括Agilent DNA微阵列在内的来自于各种各样表达格式的数据,并且还能应用Rosetta Biosoftware拥有专利的误差模型,从而使每一项基因表达测量都能够得到高质量的统计数据。Rosetta Resolver系统的分析工具能够自动利用这些统计数据,并得出最优结果。

众多生命科学研究机构也已经获得了Rosetta Resolver系统的授权,其中包括Aventis Pharmaceuticals公司、Bristol-Myers Squibb公司、GlaxoSmithKline公司和默克公司(Merck & Co., Inc)在内的全球最顶尖的制药公司,以及类似哈佛大学基因组研究中心的一流学术机构。了解关于Rosetta Resolver系统的更多信息,请访问Rosetta Biosoftware公司的网站: http://www.rosettabio.com 。 

关于Rosetta Biosoftware 公司

Rosetta Biosoftware公司是面向生命科学研究的信息解决方案领先供应商。它所开发的企业软件解决方案包括Rosetta Resolver和Rosetta Elucidator系统,能够为生命科学家提供先进的、可升级的和易于操作的分析平台,从而推动发现研究工作的开展。Rosetta Biosoftware公司是默克公司(纽约证券交易所:MRK)全资子公司Rosetta Inpharmatics LLC公司的下属业务单位。了解关于Rosetta Biosoftware公司的更多信息,请访问网站 http://www.rosettabio.com 。

前瞻性声明

本新闻包含1995 年《私人证券诉讼修正法案》界定的“前瞻性声明”。这些前瞻性声明具有一定的风险和不确定性,可能会导致实际结果与这些前瞻性声明所述的结果产生重大差别。这些前瞻性声明可能包括有关产品开发、产品潜力或者财务业绩的表述。任何前瞻性声明都不能做出保证,实际的结果可能会与所表述的内容大不相同。无论出现新信息、未来事件或其他情况,Rosetta Inpharmatics公司和默克公司都不承担更新任何前瞻性声明的义务。本新闻中的前瞻性声明应同影响默克公司业务的不确定因素一起评估,其中包括:Rosetta Inpharmatics公司的技术平台在药物研究计划中的应用程度、Rosetta Inpharmatics公司的技术在市场上接受程度的不确定性、同现有技术的竞争力以及默克公司在2004年12月31日结束年度的10-K表格中第一项的警示声明所提及的内容,连同参考中提及的有关10-Q表格及8-K表格(如有的话)中的定期报告。

Rosetta Resolver和Rosetta Elucidator是Rosetta Inpharmatics LLC公司在美国的注册商标。

联系方式:针对Rosetta Biosoftware公司 Lisa Owen,206-926-1236     或者 针对Ingenuity Systems公司 Heidi Bullock,650-381-5150

(BW)(WA-ROSETTA-BIOSOFTWARE)(MRK) Rosetta Biosoftware and Ingenuity Systems to Offer Interoperability between the Rosetta Resolver System and the Ingenuity Pathways Analysis System

SEATTLE & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jan. 25, 2006--

Rosetta Biosoftware and Ingenuity Systems today announced a collaboration to establish interoperability between the Rosetta Resolver(R) system and the Ingenuity Pathways Analysis system. Researchers will be able to easily exchange data between the two systems to leverage both systems' ability to analyze gene expression data and perform advanced pathway analysis.

"The Rosetta Resolver system is a comprehensive informatics solution for analyzing large amounts of data in preclinical and clinical studies or for research diagnostic purposes," said Yelena Shevelenko, vice president and general manager of Rosetta Biosoftware. "We are pleased to provide seamless integration between Ingenuity's pathway analysis tools and the Rosetta Resolver system to our mutual customers, allowing them to uncover mechanisms of action, predict potential toxicities, and give biological meaning to their gene expression data."

"Connecting the Ingenuity Pathway Analysis solution with the Resolver system will increase the capabilities for our joint customers to derive increased understanding and insights from gene expression data," said Tuan Nguyen, VP, Partner and Professional Services of Ingenuity Systems. "This collaboration represents an important step in our strategy to seamlessly integrate Ingenuity Pathways Analysis into the natural workflow of our customers."

The Rosetta Resolver system is developed and supported by Rosetta Biosoftware and is distributed exclusively by Agilent Technologies.

About Ingenuity Systems

Ingenuity enables researchers to model, analyze and understand complex biological systems foundational to human health and disease. The Ingenuity products include pathways analysis software and knowledge bases for biologists and bioinformaticians, and enterprise knowledge management infrastructure, content and services for leading pharmaceutical and biotechnology companies. Ingenuity was founded in 1998 and is headquartered in Redwood City, California, with offices in Germany, Switzerland, France, the United Kingdom, and Japan. For more information, visit www.ingenuity.com

About the Rosetta Resolver System

The Rosetta Resolver system is a high-capacity data storage, retrieval, and analysis solution for gene expression data. The system is ideal for life science research organizations that need to assess compound specificity or toxicity, identify new genes or therapeutic targets or compare and analyze large databases of expression profiles. The Rosetta Resolver system combines flexibility and ease of use with high-performance algorithms to produce a comprehensive solution for rapid analysis of gene expression data. The Rosetta Resolver system can accept and analyze data from a wide variety of expression profiling formats, including Agilent DNA microarrays, and applies Rosetta Biosoftware's proprietary error models to yield quality statistics for every gene expression measurement within the system. These statistics are automatically leveraged by Rosetta Resolver system analysis tools for optimal results.

Life science research organizations that have licensed the Rosetta Resolver system include many of the top pharmaceutical companies in the world, such as Aventis Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline and Merck & Co., Inc., as well as premier academic institutions such as the Harvard University Center for Genomics Research. Additional information about the Rosetta Resolver system can be found on the Rosetta Biosoftware Web site at www.rosettabio.com.

About Rosetta Biosoftware

Rosetta Biosoftware is a leading provider of informatics solutions for life science research. Its enterprise software solutions, including the Rosetta Resolver and Rosetta Elucidator systems, empower life scientists with advanced, scalable, and easy-to-use analysis platforms that accelerate discovery research. Rosetta Biosoftware is a business unit of Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc. (NYSE:MRK). More information about Rosetta Biosoftware is available at www.rosettabio.com.

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Neither Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect the business of Merck & Co., Inc. including, among others, the extent to which Rosetta Inpharmatics' technology platform can be used in drug discovery programs, uncertainty of market acceptance of Rosetta Inpharmatics' technologies, ability to compete against existing technologies, and those mentioned in the cautionary statements in Item 1 of Form 10-K for the year ended Dec. 31, 2004, and in its periodic reports on Form 10-Q and Form 8-K (if any) which are incorporated by reference.

Rosetta Resolver and Rosetta Elucidator are U.S. registered trademarks of Rosetta Inpharmatics LLC.

CONTACT: For Rosetta Biosoftware Lisa Owen, 206-926-1236 or For Ingenuity Systems Heidi Bullock, 650-381-5150

相关内容
Rosetta Biosoftware公司和Ingenuity Systems公司将提供Rosetta Resolver系统与Ingenuity Pathways Analysis系统间的互用性能
/yiliaozixun/jichuyixue/281.html
更新日期:2013-04-22 13:34:44
心脏病发作易致命谨记信号
肥胖宝宝需要进行特殊的体检项目
“心率”管理是心血管疾病患者的重中之重
手术直播 暴露病人隐私?
药商造药,也造疾病
实习观摩暴露隐私? 反思医院伦理
性可以成瘾
中国医疗在刀山火海里锤炼
这样的工作量规定——医生能不变成魔鬼?
第1期·基因番茄抗乙肝?
人人都可以参与维权
我有一个梦想![之乙肝版]
SFDA临床实验机构认证中心华西医院检查验收
犯罪精神病院的产生及其在中国的前景
中国公众营养论坛呼吁加强全民营养健康教育
治癌神话是如何打造的
卫生部批准的开展辅助生殖技术和人类精子库机构名单
人权医生呼吁利比亚释放五名保加利亚护士
伟大的发明-----宫刑
没管好食品含盐量FDA被起诉
中草药没有副作用吗? 谈“中国草药肾病变”
干细胞研究讲稿
从百赛诺看国内的乙肝药物研究
济南市儿童医院肾活组织穿刺取得成功
非典型畸胎样/横纹肌样瘤在大龄儿童中疗效良好
北京儿童医院开展婴儿游泳项目
“伟哥”变身成为治疗早期肺动脉高血压
中医存废困境:西医改造中医将致中医灭亡
中医整体观是中医的特色与优势吗
艾滋病职业暴露列入职业病 可享工伤保险等待遇
我国学者在艾滋病患者房水中首次找到HIV病毒载量
2006年1月1日起南京地区医院间医学检查检验结果互认
一味治疗让多少亲情变味 放弃治疗有时更彰显医者父母心
中国尚存大量健康贫困问题 近1亿人没有医疗服务
“赤脚医生”小史
医大盛京医院成功开展3D腹腔镜手术
安徽省立医院完成后路微创椎体血管瘤骨水泥成型术
安徽省立医院完成关节镜下自体半键股薄肌腱前交叉韧带重建术
同济医院通过医学实验室认可
争取药品大众化-药丸、专利和利润
反叛,为了人的价值──“无国界医生”组织的原则和理念
美国1973年的“病人权利典章”
英国护士不愿推迟退休年龄
世诺*瑞金眼科中心向交警发放偏光太阳镜
FDA接受TYSABRI®(natalizumab)治疗多发性硬化症的补充生物制品许可申请
排毒养颜胶囊欲盖弥彰
我院眼科成功完成高难度“翼状胬肉切除联合羊膜移植术”
省卫生厅在抗灾中践行党的群众路线
医大一院完成心脏外科最具挑战手术